We investigated the effects of the antifolate methotrexate on intracellular folate pools of human myeloid precursor cells (MPCs). Immature MPCs, representing 3.2% of the original marrow population, were selected from normal human bone marrow by immune rosetting. The intracellular folate pools were labeled by incubation with 5 X 10-" M [3H15-formyl-FH4 and were quantitated by high performance liquid chromatography. The predominant folates were 5-methyl-tetrahydrofolate (5-methyl-FH4) (36%), 10-formyl-FH4 (41.4%), 5-formyl-FH4 (12.3%), and FHf4 (10.3%). A 12-h exposure to 1 MM methotrexate (MTX) resulted in a 34% reduction in the intracellular concentration of 10-formyl-FH4, a 61% decrease in 5-formyl-FH4, and a 62% decrease in 5-methyl-FH4, as well as the appearance and progressive expansion of the FH2 and 10-formyl-FH2 pools. These changes were maximal after 4 h of incubation with MTX. Paralleling the changes in folates, particularly the increase in FH2, were a 64% reduction in myeloid colony formation and a 77% depression of de novo purine synthesis after 4 h of MTX. We conclude that MTX does not produce quantitative depletion of 10-formyl-FH4 and that its antipurine effect may be mediated by direct inhibition of de novo purine synthesis by FH2 and, at later time points, by MTX polyglutamates.
Introduction
Methotrexate (2,4-diamino,10-methylpteroyl glutamic acid; MTX)' is a tight-binding inhibitor of dihydrofolate reductase (DHFR) and has shown potent antitumor activity against human leukemia, non-Hodgkin's lymphoma, choriocarcinoma, and other human tumors (1) . Its primary toxic effects are myelosuppression and mucositis. Its antineoplastic effect as well as toxicity have been ascribed to depletion of reduced folates with consequent arrest in the synthesis of purines, thymidylate, and proteins. However, significant depletion of reduced folate pools after MTX treatment has not been demonstrated in tissue culture (2) or in vivo.
An alternative explanation for inhibition of purine and pyrimidine biosynthesis has been forthcoming from studies of the properties of the polyglutamated forms of MTX and dihydrofolate (FH2), which accumulate intracellularly during MTX ex-synthesis of thymidylate and purines, respectively.
Evidence in support of this alternative explanation of MTX action has been forthcoming from direct measurement of the folate pools in MCF-7 breast cancer cells, accomplished by labeling the intracellular folates with [3H]folic acid, followed by separation of individual folates by high performance liquid chromatography (HPLC). Exposure ofthese cells to 1 gM MTX resulted in marked inhibition of de novo purine synthesis despite only 20% depletion of 10-formyl-tetrahydrofolate (10-formyl-FH4), the substrate required for purine biosynthesis. The authors suggested that the purine biosynthetic pathway was directly inhibited by MTX and/or FH2 polyglutamates.
To determine the effects of MTX on intracellular folates in these cells, we have isolated an immature fraction of marrow cells by immune rosetting. The immature fraction thus obtained was composed of 80% myeloblasts, promyelocytes, and myelocytes (the dividing population of marrow myeloid lineage). The following study demonstrates relative preservation of the 10-formyl-FH4 pool in the presence of concentrations of MTX that were cytotoxic to myeloid colony formation. At the same time, MTX exposure led to significant expansion of pools of FH2, and the appearance of a new folate compound, IO-formyl-FH2.
Methods
Chemicals. MTX was obtained from the Drug Synthesis and Chemistry Branch, National Cancer Institute (Bethesda, MD) and was purified by DEAE-Sephacel chromatography as previously described (6) . [3',5',7,9- 3HJ-1-5-Formyl-l-4-PteGlu (specific activity, I Ci/mmol) was synthesized from [3',5',7,9-3H]PteGlu according to the methods of Moran et 12 mCi/mmol. The cells were washed three times with 2 ml of cold PBS, followed by final pelleting by centrifugation at 2000 g for 10 min. Perchloric acid, 0.5 ml of I N, was added to the cell pellet and the precipitated macromolecules were depurinated by boiling for I h. After depurination, the supernate was neutralized with I N KOH and the adenine and guanine bases separated by reverse-phase HPLC and quantitated by liquid scintillation counting of the separated fractions as previously described (18) .
Results
Myeloid precursor cell enrichment. Mononuclear (Fig. 1) . The identity of the 10-formyl-FH2 peak on HPLC was verified by its quantitative conversion to 10-formyl-FH4 in the presence of DHFR (2) and by its catalytic activity as a substrate for AICAR transformylase.
Increasing the MTX concentration from 0.1 to 1 gM for 2 h caused further changes in the reduced folate pools, particularly an additional decrease in 5-methyl-FH4 and a complete disappearance of FH4. In contrast, the pool of 10-formyl-FH4 was relatively preserved, the maximal decrease to 65% of the pretreatment level occurring at 1 gM MTX. A further increase in MTX concentration to 10 gM had little additional effect, except for a small increase in the pool of l0-formyl-FH2 (Fig. 1) .
In addition to the changes in intracellular distribution of folates, MTX caused a dose-related decrease in the total intracellular folate content (Table II) to a maximum of65% ofcontrol 4 h after exposure to 10 MM MTX. The monoglutamated fraction, which constituted 20% of intracellular folates in control Background counts in the HPLC eluate averaged 50 dpm, while the folate cofactor peaks were 50-300 dpm over background in a typical experiment. cells, decreased to 14% of the total folates in the presence of I ,uM MTX for 4 h.
We next examined the time course ofthe intracellular folate changes after exposure to i ,uM MTX (Fig. 2) . The main effects, a rapid decrease in the 5-methyl-FH4 (Fig. 2 F) and a reciprocal increase in FH2 (Fig. 2 B) and 10-formyl-FH2 (Fig. 2 C) , were measurable after 2 h of exposure, with little further change after 12 h of incubation with MTX. There was a 38% decrease in 10-formyl-FH4 at 2 h, but no further reduction at later time points.
To correlate these changes with the effect of MTX on the of the control after 2 h of MTX and to 23±10% after 4 h of MTX exposure, despite the fact that the folate cofactor for purine biosynthesis, 10-formyl-FH4, decreased by only 38% at 2 h, and remained at this concentration thereafter. Cytotoxic effect ofMTX on CFU-C. To verify that the conditions used in these experiments were cytotoxic to myeloid cells, 2 X 105 MPCs in sample, were incubated with 0.001-10 AM MTX for 12 h and the ability of these cells to form colonies was assessed. A decrease of 24% in CFU-Cs was observed after 0.1 ,gM MTX for 12 h, 64% after 1 MM MTX, and 84% after 10 ,uM MTX. These changes parallel the expansion of the intracellular FH2 pool, which was 50% of its maximal value at 0.1 X 1o-6 M and was maximal at 1 X 1o-6 M (Fig. 3) .
The cytotoxic effect of MTX is attributed to its inhibitory effect on both the pyrimidine and purine synthesis. The distribution of intracellular folates found in myeloid precursor cells resembles that found in intestinal mucosa, but differs from that of nondividing tissue. According to microbial assays, 5-methyl-FH4 is the primary folate found in nondividing tissues such as liver (8, (33) (34) (35) , kidney (33), or red blood cells (36) . In contrast, the predominant folate in rapidly growing tumor cells is 10-formyl-FH4 (34, 37, 38) , the required cofactor for the AICAR transformylase and glycinamide ribonucleotide (GAR) transformylase reactions in the purine synthetic pathway.
These two folate forms (5-methyl-FH4 and 10-formyl-FH4) are present in equal concentrations in intestinal mucosa (34) and, according to the present study, in the immature myeloid fraction of normal marrow, indicating the intermediate proliferative potential ofthe cell fractions used in these experiments. It is possible that a more highly purified myeloblast fraction would contain higher levels of 10-formyl-FH4.
